Ipsen is a global biopharmaceutical group dedicated to improving lives and health outcomes through innovative medicines in Oncology, Neuroscience and Rare Disease. We also have a well-established and successful Consumer Healthcare business. We are committed to discovering new treatments in areas with high unmet medical needs and improving the quality of life for patients.
We have 90 years of heritage as a family-owned company and a publicly traded business.
We sell more than 20 drugs in 115 countries and have a direct commercial presence in over 30 countries worldwide.
We focus on Specialty Care with businesses in Oncology, Neuroscience and Rare Disease, as well as a Consumer Healthcare business.
We have over 5,700 employees worldwide, who are based at our many sites, including 8 R&D sites and industrial sites.
We are proud that 15.1% of our sales are reinvested in R&D, some €388.8m in 2019.
In 2019, total sales exceeded €2.5bn and we are seeing double digit growth in Europe and growth of almost 20% in North America.
We are one of the world’s top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen is a global biopharmaceutical group dedicated to improving lives and health outcomes through innovative medicines in Oncology, Neuroscience and Rare Disease. We also have a well-established and successful Consumer Healthcare business. We are committed to developing new treatments in areas with high unmet medical needs and improving the quality of life for patients.
2019 was a record year for us, with strong growth in all areas of our business – our products are number one or two in patient share in our key therapeutic areas and we have seen double-digit growth in Europe and growth of almost 20% in North America.
In 2019, we reported Group net sales which exceeded €2.5 billion for the first time, representing a 14.8% growth in sales.
I am excited to see the exceptional progress made by our Specialty Care business, with sales growing by more than 17%. Somatuline achieved double-digit growth, fueled by its strong performance and the uptake of our new and differentiated device in North America and Europe. The performance of our Oncology franchise was also driven by the launches of Cabometyx across geographies and indications as well as solid sales growth for Onivyde and Decapeptyl. Our Neuroscience business continued to demonstrate strong momentum thanks to the solid performance of our neurotoxin, Dysport, in the therapeutics and aesthetics markets.
We also continued the transformation of our Consumer Healthcare division as a sustainable and autonomous business, which was back to growth in the second half of 2019.
And finally, we made significant strides in building a leading Rare Diseases franchise for the next decade. Despite the recent setback with the palovarotene program, we remain committed to bringing potential solutions to FOP patients as quickly as possible.
Our growth story continues
Last year was another excellent year of operating performance for Ipsen, with continued improvements in our profitability. For the first time, our core operating margin surpassed 30% of net sales, while we continued to increase our R&D investments reaching the level of 15% of net sales. Our pipeline has never been as rich as it is today, with several significant Phase 3 or registration trials scheduled for 2020 – the most ever!
As we look to the future, we have a solid roadmap in place to sustain our growth, our pipeline and our culture. There will be no change in our strategy and no pause in our transformation. Our vision of being a leading global biopharmaceutical company focused on innovation and Specialty Care and our mission to improve patients’ lives through innovative new medicines remain the same.
Together, we are committed to a disciplined execution of our strategy, further advancing our R&D pipeline programs and delivering another year of solid sales growth in 2020 and beyond.”
Aymeric Le Chatelier,
Chief Financial Officer at Ipsen
* members of the Executive Leadership Team
Chief Executive Officer
David Loew was appointed as Chief Executive Officer of Ipsen on July 1, 2020.
Prior to joining Ipsen, David was CEO of Sanofi Pasteur Vaccines. During his tenure, he piloted a successful worldwide growth strategy via acquisitions and licensing deals.
David brings nearly 30 years of leadership and experience across a range of therapeutic areas, including oncology, CNS and cardio-metabolism, as well as consumer healthcare. He has worked in the U.S., European and international markets. He began his career at Coopers & Lybrand and Hewlett Packard in 1990 before joining Roche in 1992. Over the following two decades, David held a variety of positions, including Global Oncology Head, Global Chief Marketing Officer & Head of Global Product Strategy and Region Head, Eastern Europe, Middle East and Africa for the Pharma Division of Roche. He joined Sanofi in July 2013 as Senior Vice President, Commercial Operations Europe, where he was responsible for the prescription, consumer healthcare and generics business across the EU region.
David has served on the board of the Global Alliance for Vaccines and Immunization (GAVI), chaired the Steering Committee of IFPMA and has strong connections with global organizations, including the WHO, UNICEF, the Bill & Melinda Gates Foundation, as well as American health agencies, including BARDA and the NIH.
David earned his BA in Business Administration and MBA from the University of St. Gallen, Switzerland.
Bartosz (Bartek) Bednarz*
Executive Vice President,
Head of Global Product and Portfolio Strategy
Bartosz (Bartek) Bednarz, DDS, is Executive Vice President, Head of Global Product and Portfolio Strategy at Ipsen, which covers Global Franchises, Global Value and Access, Global Policy and Global Strategic Business Excellence. Bartosz joined Ipsen in 2017 and has 20+ years of pharmaceutical leadership experience.
Before assuming an EVP role, Bartosz successfully led Ipsen’s Oncology franchise. Prior to that, he held global leadership roles at AstraZeneca and Novartis. At AstraZeneca, where Bartosz spent seven years, he started as Country President and later led new launches in Oncology as well as Oncology Commercial Operations at a global level while based in Cambridge (UK). At Novartis, Bartosz held various commercial leadership roles at local, regional and international levels around the world, including Poland, Spain, Switzerland and Canada. He has worked across multiple therapeutic areas and is very passionate about all three TAs at Ipsen: Oncology, Rare Disease and Neuroscience.
Bartosz Bednarz is a Doctor of Dental Medicine. He obtained his diploma with honors at the Medical University of Pomerania in Poland.
Executive Vice President, Strategy & Transformation
Dominique Bery joined Ipsen in April 2017.
Dominique spent the previous 18 years with McKinsey & Company, where she was elected Partner in 2010. Dominique co-led the Pharmaceuticals and Medical Products Practice in Europe and served multiple pharmaceutical and biotech companies. She also worked with diagnostics companies, hospitals, payors, ministries of health, patient associations, and public health organizations, gaining extensive experience in the healthcare industry.
Located in Paris and Washington, Dominique led many company-wide transformation projects across Europe, US and Africa, working hand in hand with management and their teams. She supported clients to set their strategic priorities at corporate, business unit, and therapeutic area level, and she worked with a number of brand teams to accelerate brand performance. She brings a truly cross-functional perspective, having worked closely with most functions in pharmaceutical companies. In parallel, she initiated the creation of a community of women executives in France, focused on developing the capabilities of women executives on key business topics such as innovation, leadership in transformation, business model disruption.
Dominique is a graduate from ESSEC and holds a Masters in Business Administration from Harvard Business School.
Executive Vice President,
François Garnier was appointed Executive Vice-President, General Counsel in December 2014.
François began his career in 1989 at Servier S.A. as International Contracts Manager, and remained with the company until September 1995. He then moved to Rhône Poulenc Rorer S.A. to take up the position of Counsel for Corporate Transactions. In 1996 he moved to the United States as Associate Counsel, before being appointed Chief Counsel for France in 1999. François continued his career as Chief Counsel at Aventis Animal Nutrition until 2001, when he joined the Pharmacia Group as Chief Counsel for Europe.
Francois joined Pfizer France in 2003, as Vice-President, General Counsel before moving on to become Chief Counsel for Pfizer’s operations in Europe from 2009 to 2014. He was International Chief Counsel (ex-US) for Pfizer Inc. from January 2014.
A student from the IEP in Paris, Francois graduated from the University of Panthéon-Assas prior to working in the legal departments of a number of pharmaceutical groups.
Executive Vice President,
Benoît Hennion has been Executive Vice-President, Consumer Healthcare since March 2017.
Benoît joined Ipsen in 2006 within the Corporate Strategic Planning team. In 2009, he became Business Unit Head, and subsequently in 2011, General Manager France leading both Specialty Care and Consumer Healthcare. In 2014, Benoît was appointed Vice President Asia-Pacific Specialty Care, based in Seoul, Korea for three years. Benoît gained his MBA degree at ESSEC (Paris, France). Before joining Ipsen, he started his career at Société Générale in the Czech Republic and then served for six years in the Paris office of Roland Berger Strategy Consultants.
Steven Hildemann*, M.D., PhD
Executive Vice President,
Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs
Steven Hildemann, M.D., PhD, is Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs at Ipsen.
Prior to joining Ipsen, Dr.Hildemann held leadership roles in science-based bioethics and built an innovative digital health startup in cancer care after serving for five years as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety at Merck. He also held several strategic leadership positions with biopharmaceutical companies such as Pharmacia-Pfizer and Schering-Plough-MSD.
Dr Hildemann is board certified in internal medicine and cardiology with broad clinical training across internal medicine including medical oncology, gastroenterology, rheumatology and pulmonary oncology at university hospitals in Munich, Germany. Throughout his career, he has engaged in part-time clinical practice, late-stage pharmaceutical research and medical teaching. Dr. Hildemann received his MD-PhD at the Albert Ludwig University of Freiburg, Germany, where he continues to serve as an adjunct Professor of Medicine.
Executive Vice President,
Ethics and Social Responsibility Officer
Dominique Laymand was appointed Executive Vice-President, Chief Ethics and Compliance Officer in October 2017.
Dominique Laymand joined Ipsen in 2015 as Senior Vice-President, Chief Ethics and Compliance Officer.
Dominique is in charge of Ethics & Compliance strategy for the Ipsen Group, the deployment of the Global Ethics & Compliance program and the organization of this department. The Global Ethics & Compliance program is based on an integrated approach to prevention and management of operational risks, as well as on strong principles of integrity and ethics in the conduct of business.
Previously Dominique served as Vice-President Ethics & Compliance at Bristol Myers Squibb, setting up and managing the Ethics & Compliance Europe, Middle East, Africa, Turkey and Russia program.
Dominique also chairs the committee of compliance at the European Federation of Pharmaceutical Industries and Associations (EFPIA) and also at the French Association of Pharmaceutical Industries (Leem).
Dominique is the president of ETHICS, an association which includes international professionals in Ethics and Compliance working in the healthcare sector.
Aymeric Le Chatelier*
Group Chief Financial Officer
Aymeric Le Chatelier was appointed Executive Vice-President, Group Chief Financial Officer in November 2014.
Aymeric Le Chatelier, a graduate from HEC Business School, started his career at Arthur Andersen. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer. He was subsequently appointed Financial Director of Enedis and member of the Management Board.
Aymeric served as interim Chief Executive Officer of the Group from 1 January 2020 until David Loew was appointed Chief Executive Officer on 1 July 2020.
Executive Vice President,
Chief Business Officer
Philippe Lopes-Fernandes joined Ipsen as Executive Vice President and Chief Business Officer in 2020. With more than 20 years of leadership and expertise in global business development and acquisitions within the pharmaceutical industry, Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of Oncology, Neuroscience and Rare Diseases. He has an extensive track record of creating successful business development deals in multiple therapeutic areas in Europe, Asia and North America.
Prior to joining Ipsen, Philippe worked at Merck KGaA where he was the Senior Vice President, Global Head of Business Development and Alliance Management. Before that, he held a variety of roles at Merck KGaA in Business Development, Mergers & Acquisitions, Finance and Marketing in Germany, France, Portugal, Switzerland and the United States.
Philippe received his degree from the Institut Supérieur de Gestion (ISG) in Paris in 1994. He is a French External Trade advisor (Conseiller du Commerce Extérieur) and board member of several companies. He is based in Cambridge, Massachusetts.
Howard Mayer*, M.D.
Executive Vice President,
Head of Research and Development.
Howard Mayer, M.D., is Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals. Dr. Mayer joined Ipsen in 2019 from Shire, where he was Chief Medical Officer, responsible for the hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas.
Previously, Dr. Mayer served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Prior to that, he held a variety of global roles at Pfizer, including Head, Clinical Development and Medical Affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as Director of Clinical Research at Bristol-Myers Squibb.
Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the board of directors for Genocea Biosciences and Entasis Therapeutics, and on the board of Autism Speaks in New England. He was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry in both 2011 and 2017.
Chief Human Resources Officer
Régis Mulot joined Ipsen Pharma, in March 2018, as Executive Vice President, Chief Human Resources Officer
Régis Mulot joins Ipsen from Staples Inc., the global specialty retail and e-commerce company, where he served as Executive Vice-President, Chief Human Resources Officer, leading a global team of over 600 professionals. Prior to his career with Staples (2009-18), Mr Mulot held HR leadership positions with Levi Strauss & Co (2002-08) and the technology start-up Broadnet Europe (2000-02), following earlier roles at GTECH Corporation (1994-2000), International Post Corporation (1991-94) and Chronopost SA (1989-91).
Mr Mulot served on the Board of Trustees, Simmons College (Boston M.A.); is Past Chairman of the Business Advisory Committee of the Simmons School of Management 2014-2017; Founder and former chair of the French-American HR Forum since 2016-2018. He has been Co-chair of the Boston CHRO (Chief Human Resources Officers) Leadership summit between 2014 and 2018, and is a Gartner CHRO Leadership Board member since 2017.
Mr Mulot holds a DESS Entreprises Publiques (Master in Public Administration) from Paris XI-Sud in partnership with Paris IX-Dauphine and Institut International d’Administration Publique (IIAP). He also holds a Maîtrise Droit Public (Bachelor of Law) from Paris II–Panthéon-Assas, and is a Beta Gamma Sigma honoree from the Simmons College Chapter.
Dr Aidan Murphy was appointed Executive Vice-President, Technical Operations, effective 1st January 2018. Dr Murphy has more than 25 years experience in the pharmaceutical and biotechnology industry, and since joining Ipsen in 2006 has held a number of manufacturing leadership roles in many countries.
Since 2014 Dr Murphy has held the position of Senior Vice President Biologics Development and Manufacturing at Ipsen. Also during his tenure at Ipsen, he has led the manufacturing sites of Tianjin (China), Dublin (Ireland), and Wrexham (UK) and occupied global roles as SVP CMC (Chemistry, Manufacturing, and Controls) Development & Engineering and Head of Specialty Care Manufacturing. He holds a PhD in organic chemistry from Trinity College, Dublin.
Chief Executive Officer,
At Ipsen North America
Since joining Ipsen in February 2018 as the North America Chief Executive Officer, Richard has been responsible for expanding and driving continued growth in both the U.S. and Canadian markets across key therapeutics areas of oncology, neuroscience and rare diseases. Richard has more than 25 years of global biopharmaceutical industry experience with notable achievements for his leadership, vision, and exceptional execution in growing businesses, both in the US and internationally. He has a patient-focused mindset and a proven track record of successfully building high-performing, customer-centric teams. At Ipsen, Richard serves as a member of the Executive Leadership Team and chairs the Global Business Operations leadership team.
Prior to joining Ipsen, Richard had a 10-year career at Amgen where he held varying leadership positions across Europe and North America, including, Vice President and General Manager of Amgen’s U.S. Oncology Business Unit. Prior to that, he was the Vice President of Marketing for its U.S. Oncology Business, Vice President and General Manager of Amgen Germany, and General Manager of Amgen Central & Eastern Europe. Prior to joining Amgen, Richard held a number of global leadership positions at Pfizer Inc., including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic as well as positions in marketing and market access. Richard also previously held a variety of sales, marketing, and market access roles with increasing seniority at GlaxoWellcome in Canada.
Richard serves as a member of the BIO Health Section Governing Board (HSGB), the Karyopharm Therapeutics Board, Boston Police Athletic League Board and as an interim director on the PhRMA Board of Directors.
Richard earned his undergraduate degree in Commerce from the University of Saskatchewan, Canada, and his MBA from the University of Toronto, Canada.
Executive Vice President,
Specialty Care International
Patrice Zagame was appointed Executive Vice President, Specialty Care International on September 2nd 2020. He will be responsible for all regions except the US and Canada. Patrice joined Ipsen on May 2020 in the role of Senior Vice President, Head of International for the Specialty Care organization.
Prior to joining Ipsen, Patrice was based in Brazil, where he worked as an investor, board member and entrepreneur. Patrice also previously held the roles of President & Executive VP Intercontinental at Baxalta. Before that, Patrice worked as Country President at Sanofi and Novartis in France, Brazil, Spain and Venezuela.
He began his career at Rhone Poulenc Rorer as assistant product manager, later moving to a district director role. He has also been Business Franchise Manager and Head of Oncology at Glaxo Wellcome. Patrice holds a Master’s in Business Administration (MBA) from the International Institute for Management Development in Switzerland and a doctorate in medicine from the Sorbonne University, Pierre and Marie Curie in France.
Board of Directors
The Board of Directors ensures that the company’s shareholders and the general public are provided with accurate information. It ensures that the company has reliable procedures for identifying, measuring and monitoring its commitments and risks, as well as adequate financial and operational internal controls.
Chairman of the Board of Directors
Marc de Garidel
MARC DE GARIDEL – CHAIRMAN OF THE BOARD OF DIRECTORS
Marc de Garidel joined Ipsen as Chairman and Chief Executive Officer in November 2010. He has been the Ipsen Chairman of the Board of Directors since July 2016.
Marc de Garidel is also Chief Executive Officer and Director of AZTherapies, Inc. since October 1st, 2020. He was previously, for 2 years and a half, Chief Executive Officer and Director of Corvidia Therapeutics, Inc. which was sold to Novo Nordisk in July 2020.
Marc de Garidel started his career with the group Eli Lilly and pursued at Amgen, from 1995 to 2010, with increasing responsibility positions in the US and Europe.
Marc de Garidel is Director of Claris Biotherapeutics since July 2020.
Previously, he was Director of several biotechnology companies, including Vice-Chairman of the Board of Directors of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the Board since 2015.
Marc de Garidel is a graduate from the French Engineering School ESTP and has an Executive MBA from Harvard Business School.
The Board of Directors has set up six permanent committees and has defined both the composition and powers of these committees.
April 2019: Acquisition of Clementia Pharmaceuticals
Paris, 18 April 2019 – Ipsen and Clementia Pharmaceuticals announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court.
Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases.
Early 2017: Acquisition of oncology assets from Merrimack pharmaceuticals
Paris (France), 9 January 2017 – Ipsen announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection. The transaction represents a unique opportunity and a strong strategic fit for Ipsen. ONIVYDE is a clinically differentiated and FDA-approved product for patients with high unmet medical needs.2017
March 2016: Ipsen’s oncology pipeline was reinforced by a licensing deal with Exelixis
Exelixis, Inc. and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug. Under the agreement, Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan, including COMETRIQ®, which is currently approved in the European Union (EU) for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). The companies have agreed to collaborate on the development of cabozantinib for current and potential future indications. Exelixis will maintain exclusive commercial rights for cabozantinib in the United States and Canada, and continue its discussions to partner commercial rights in Japan.
April: Ipsen opened its new peptide-driven R&D center in Cambridge (USA).
- April 1st: Ipsen opened its new peptide-driven R&D center in Cambridge (USA).
- May, 19: Ipsen strengthened its oncology expertise with the acquisition of OctreoPharm Sciences, a German company developing innovative radiopharmaceutical products for the diagnosis and treatment of neuroendocrine tumors.
- July 18: The Food and Drug Administration approved botulinum toxin DYSPORT® as a treatment for adult upper-limb spasticity in the US.
- August,3: Ipsen’s partner Lexicon Pharmaceuticals announced positive results from a late-stage trial that evaluated the efficacy and safety of telotristat etiprate for carcinoid syndrome patients with advanced neuroendocrine tumors whose symptoms are inadequately controlled by somatostatin analogs.
- Ipsen strengthened its primary care portfolio with the launch in France of strawberry-flavored SMECTA® and SMECTALIA® stick for adults, an OTC ready-to-use formulation of SMECTA®.
Ipsen’s SOMATULINE® DEPOT® gets FDA approval
- SOMATULINE® DEPOT® (lanreotide) Injection 120 mg (referred to as SOMATULINE®) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Pancreatic and gastrointestinal neuroendocrine tumors are rare cancers. There are an estimated 112,000 individuals currently living with pancreatic and gastrointestinal neuroendocrine tumors in the U.S
- Ipsen announces FDA acceptance of filing for DYSPORT® in the treatment of upper limb spasticity in adult patients
- Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences. The 2011-2014 collaboration enabled significant steps forward in the understanding of basic biological mechanisms. Ipsen to support innovative Salk investigations into biology for another three years
- The Fondation Ipsen celebrates its 30th anniversary with a prestigious conference on the perspectives of cancer research, “Biology viewed through the prism of cancer”, attended by 8 Nobel Prize laureates and the greatest scientists in biomedical research.
Teijin Pharma Limited and Ipsen launched SOMATULINE® in Japan
- Teijin Pharma Limited and Ipsen launch of SOMATULINE® 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism.
- Ipsen and Inspirations Biopharmaceuticals announce closing of the sale of OBI-1 and Milford facility to Baxter International
- Health Canada has granted amarketing authorization for DYSPORT® for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market DYSPORT® for use in aesthetic medicine in Canada.
- Christel Bories joins Ipsen as Deputy CEO. Working alongside Marc de Garidel, Chairman and CEO, Christel Bories is responsible for accelerating the execution of the Group’s strategy.
- Ipsen strengthens its neurology R&D capabilities with the acquisition of Syntaxin, a leader in recombinant botulinum toxin technology.
Ipsen enters into a research partnership with Oncodesign to develop new therapeutic agents
- Ipsen and Active Biotech present encouraging results from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer and initiate a new phase II, proof-of-concept clinical trial to evaluate the safety and efficacy of tasquinimod in other cancer indications.
- SOMATULINE® receives marketing authorization in Japan for the treatment of acromegaly and pituitary gigantism and becomes Ipsen’s first drug available worldwide.
- Inspiration Biopharmaceuticals, Inc., Ipsen’s partner, initiates a voluntary reorganization plan of its activities under the Chapter 11 of US Bankruptcy Code.
Ipsen announces a new development strategy based on three pillars
Ipsen announces a new comelopment strategy based on three pillars:
- Focus resources and investments on specialty care
- Invest to grow through the comelopment of new compounds and product life-cycle management programs
- Leverage the full potential of the Group’s geographical footprint
Ipsen and the Salk Institute renew the “Ipsen Life Sciences Program” for a further three years.
Syntaxin and Ipsen enter into a strategic agreement to comelop novel botulinum-toxin therapeutics.
Ipsen strengthens its business in urology-oncology with the acquisition of the rights to HEAVY® (a drug aimed at improving bladder cancer detection) and the establishment of two significant partnerships with: Active Biotech for the co-comelopment and commercialization of tasquinimod (a molecule for the treatment of metastatic and castration-resistant prostate cancers), and Institut Gustave Roussy in the area of medical oncology to leverage the combined expertise of their respective R&D teams.
Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership
- Ipsen and Inspiration Biopharmaceuticals Inc. enter into a partnership to create a hemophilia franchise.
- Ipsen increases its presence in oncology and endocrinology in South-East Asia through a commercialization agreement with Invida.
- Ipsen grants Menarini exclusive license rights to ADENURIC® (for the treatment of chronic hyperuricemia in gout) in 41 countries. Ipsen retains co-promotion rights in France.
- Ipsen and Rhythm Pharmaceuticals, a biotechnology company comeloping peptide therapeutics for metabolic diseases, enter into a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.
- Ipsen grants Rhythm an exclusive worldwide license for research, comelopment, and commercialization of its melanocortin and ghrelin programs originating from Ipsen’s research.
- Marc de Garidel is appointed Chairman and Chief Executive Officer
Ipsen and Galderma receive collective green light for AZZALURE® from 15 European countries
- Ipsen and Galderma receive collective green light for AZZALURE® from 15 European countries’ Health Authorities for the granting of national marketing authorizations for the treatment of glabellar lines.
- AZZALURE® receives marketing authorization in the UK, France and Germany. The FDA approves DYSPORT™ for therapeutic and aesthetic use.
- The European Medicines Agency (EMA) delivers marketing authorization for the 6-month formulation of DECAPEPTYL® in nine European countries. The product is launched in France
Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego)
- Ipsen initiates a partnership with the Salk Institute for Biological Studies (San Diego, US) aimed at improving understanding of proliferative and degenerative diseases.
- Ipsen reinforces its presence in the US with three acquisitions: Tercica Inc. in endocrinology, APOKN® in neurology and Vernalis’ US commercial operations, and all assets related to OBI-1 from Octagen in hematology.
The Group enters into a partnership with Galderma
- The Group enters into a partnership with Galderma, for the comelopment, promotion and distribution of the Group’s botulinum toxin type A in aesthetic medicine indications.
- SOMATULINE® DEPOT obtains marketing authorization in the United States for the treatment of acromegaly. SOMATULINE® DEPOT is the first product stemming from Ipsen’s R&D to be approved by the FDA.
- Ipsen’s shares are admitted to the SBF 120 index in France.
Ipsen enters into an agreement with Medicis (now Valeant)
- Ipsen enters into an agreement with Medicis (now Valeant) to market its botulinum toxin in aesthetic medicine indications in the US, Canada and Japan.
- Ipsen and Tercica complete worldwide strategic collaboration agreement in Endocrinology. Ipsen grants Tercica exclusive rights to market SOMATULINE® AUTOGEL® in the United States and in Canada.
- Tercica grants Ipsen exclusive rights to market INCRELEX™, a leading product in the United States for the treatment of short stature associated with severe primary IGF-1 deficiency in all territories excluding the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa.
Ipsen’s shares are listed on Euronext Paris.
- Ipsen’s shares are listed on Euronext Paris.
- Ipsen enters into a licensing agreement with Radius through which Radius acquires the exclusive worldwide rights (excluding Japan) to develop, manufacture and distribute Ipsen’s osteoporosis proprietary molecule.
The Group opens a botulinum toxin manufacturing facility in Wrexham
- The Group opens a botulinum toxin manufacturing facility in Wrexham (United Kingdom).
Ipsen and Teijin enter into an agreement to develop and market four Ipsen products
- Ipsen and Teijin enter into an agreement to develop and market four Ipsen products, notably SOMATULINE® AUTOGEL®, in Japan and a Teijin product for the treatment of gout in Europe.
Ipsen launches SOMATULINE® AUTOGEL® in the UK, France followed by many other countries.
- Ipsen launches SOMATULINE®AUTOGEL® in the UK, France followed by many other countries, strengthening Ipsen’s competitive position. To the Group’s knowledge, SOMATULINE® AUTOGEL® is the first semi-solid formulation for injection without any excipient, since the active substance controls the sustained release.
The Group is opening a manufacturing facility in China.
- The Group is opening a manufacturing facility in China. This facility will manufacture SMECTA® for the Chinese market, which is a reference treatment in the country.
Ipsen launches FORLAX®, a product used for the treatment of constipation.
Ipsen launches FORLAX®, a product used for the treatment of constipation.
The Group launches SOMATULINE®, a sustained-release peptide...
- The Group launches SOMATULINE®, its sustained-release peptide for the treatment of acromegaly and neuroendocrine tumors in France.
Ipsen acquires Speywood, the company that developed DYSPORT®
- Ipsen acquires Speywood, the company that developed DYSPORT® for the treatment of movement disorders and various forms of muscular spasticity.
- This acquisition strengthens the Group’s presence in the UK and Northern Europe.
- Ipsen establishes a sales platform for its biological product and opens an office in Russia.
Ipsen begins its development in China, with the opening of a representative office...
- Ipsen begins its development in China, with the opening of a representative office in Tianjin.
The Group creates La Fondation Ipsen under the aegis of the Fondation de France
The Group creates La Fondation Ipsen under the aegis of the Fondation de France. Its mission is to foster interactions between leading scientists in the field of life sciences.
Ipsen initiates a partnership with Debiopharm....
- Ipsen initiates a partnership with Debiopharm. This collaboration leads to the marketing of DECAPEPTYL® in 1986. This analogue of natural GnRH hormone (or gonadotropin) is indicated for the treatment of prostate cancer, endometriosis and infertility. DECAPEPTYL® has been a key driver of the Group’s international expansion.
The Group enters an expansion phase...
- The Group enters an expansion phase with the launch of GINKOR®, TANAKAN® and SMECTA®. The Group creates Laboratoires Ipsen (Institute of Synthetic Products from Natural Extraction).
The Group opens its first research facility in Les Ulis (France).
- The Group opens its first research facility in Les Ulis (France).
The Group launches Citrate de BETAïNE®
- The Group launches Citrate de BETAïNE®,a product used in the symptomatic treatment of dyspepsia.
Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France)
- Dr. Henri Beaufour creates Laboratoires Beaufour in Dreux (France) to launch ROMARÉNE®, a product derived from rosemary for the treatment of digestive disorders.
Mid-term financial outlook and capital allocation strategy
Ipsen provides its financial outlook for the period 2020-20241:
- Group Net Sales CAGR2 between +2% and +5%3,assuming potential additional indications
- Commitment to invest in R&D supported by SG&A efficiencies
- Lower SG&A as a percentage of net sales driven by further focus and optimization
- Higher R&D as a percentage of net sales driven by external innovation strategy
External innovation is Ipsen’s number one priority for capital allocation. In support of its external innovation strategy, Ipsen expects to generate by 2024 a cumulative €3bn4 of firepower for pipeline expansion, excluding the sale of any assets.
1 Ipsen is on track to deliver its previous 2022 financial targets and is committed now to a new 2024 financial outlook
2 Compound Annual Growth Rate
3 At constant exchange rates and scope
4 Based on Net Debt remaining below 2.0x EBITDA